Perspective Therapeutics (CATX) director awarded 50,000-share stock option grant

Rhea-AI Filing Summary

Perspective Therapeutics director Maria E. Martinez received a grant of stock options, giving her the right to buy 50,000 shares. The award, approved by the board as her annual 2026 equity grant, was granted on March 2, 2026 and carries a zero exercise price. The option vests in full on March 2, 2027, as long as she continues serving through that date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Martinez Maria E

(Last) (First) (Middle)

C/O PERSPECTIVE THERAPEUTICS, INC.

2401 ELLIOTT AVENUE, SUITE 320

(Street)

SEATTLE WA 98121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Perspective Therapeutics, Inc. [ CATX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$5.35	03/02/2026(1)		A		50,000		(2)	03/02/2036	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026.

2. Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date.

	/s/ Maria E Martinez by Chris Nenno, as Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CATX director Maria E. Martinez report?

Maria E. Martinez reported receiving a stock option grant for 50,000 shares. This option is an annual 2026 equity award approved by Perspective Therapeutics’ board, providing her the right to acquire shares under specified vesting conditions and timing.

How many Perspective Therapeutics (CATX) stock options were granted to Maria E. Martinez?

She was granted stock options covering 50,000 shares of Perspective Therapeutics common stock. This entire amount reflects her 2026 annual equity award, as disclosed in the Form 4 insider transaction report.

What is the grant date of Maria E. Martinez’s 50,000 CATX stock options?

The grant date for the 50,000-share stock option award is March 2, 2026. The board of directors approved the option grant on January 26, 2026 as her annual equity award for the 2026 year.

When do Maria E. Martinez’s CATX stock options vest?

The stock options vest in full on March 2, 2027. Vesting is contingent on Maria E. Martinez continuing to serve in her role with Perspective Therapeutics through that vesting date, according to the Form 4 footnote disclosure.

What is the exercise price of Maria E. Martinez’s CATX stock options?

The reported exercise price for the 50,000 stock options is $0.00 per share. This means she can acquire the underlying shares without paying a cash exercise price, subject to vesting and other award terms.

Why did Maria E. Martinez receive this CATX option grant?

The option represents Maria E. Martinez’s annual equity award for 2026 from Perspective Therapeutics. It was approved by the company’s board of directors as part of director compensation, aligning her interests with shareholder value over time.